Dr. Pinato Discusses Pheochromocytomas and Paragangliomas

David James Pinato, MD, MRCP, PhD
Published: Monday, Jul 10, 2017



David J. Pinato, MD, PhD, NIHR Academic Clinical Lecturer in Medical Oncology, resident, Royal Brompton Hospital and Imperial College London, discusses pheochromocytomas (PCC) and paragangliomas (PGL).

PCCs and PGLs are very rare types of neuroendocrine tumors with poor prognoses, with 20% to 30% of patients either recurring after surgery, or presenting with metastatic disease for which there are no effective treatments.

When the interplay between hypoxia and the regulation of PD ligands were investigated, Pinato says that 15% to 20% of patients with PCCs and PGLs displayed an upregulation of either PD-L1 or PD-L2, suggesting that these 2 targets are somehow involved in the immune tolerogenic environment of these tumors.
 


David J. Pinato, MD, PhD, NIHR Academic Clinical Lecturer in Medical Oncology, resident, Royal Brompton Hospital and Imperial College London, discusses pheochromocytomas (PCC) and paragangliomas (PGL).

PCCs and PGLs are very rare types of neuroendocrine tumors with poor prognoses, with 20% to 30% of patients either recurring after surgery, or presenting with metastatic disease for which there are no effective treatments.

When the interplay between hypoxia and the regulation of PD ligands were investigated, Pinato says that 15% to 20% of patients with PCCs and PGLs displayed an upregulation of either PD-L1 or PD-L2, suggesting that these 2 targets are somehow involved in the immune tolerogenic environment of these tumors.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Frontiers in Immuno-Oncology for Microsatellite Instability-High CancersAug 29, 20182.0
Oncology Briefings™: Updates in Rare Hematology: Advancing Care and Improving Outcomes for Patients with Aplastic AnemiaAug 31, 20181.0
Publication Bottom Border
Border Publication
x